Anavex Life Sciences Corp (AVXL)

[falconer66a]

Significant Findings Revealed.

Got to listen to Dr. Missling’s presentation.

https://www.anavex.com/wp-content/uploads/2019/09/Janney-Audio-Presentation-Sept-2019.mp3

Lots of information; but the very best, I think is between 17:58 and 21:17, when Missling reveals that the Australian Alzheimer’s patients on the high dose of Anavex 2-73 for 57 weeks had improved scores of activities of daily living.

At three years (148 seeks), “activities of daily living almost not declining....” The plot line is almost flat. Cognition, too, continues during the period without notable decline.

Simply, then, Anavex 2-73, at the right dosage, essentially stops the progression of mental decline caused by Alzheimer’s disease, at least for three years.

Compare that to the results of Aricept (donepezil), the preferred FDA-approved Alzheimer’s disease treatment drug. It merely slows the progression of the disease, and only for a period, often just for a few months. Debility and death universally ensue.

Aricept is the standard of care (SOC). The Australian Alzheimer’s patients taking proper dosages of Anavex 2-73 have had, for three years, their disease effectively treated. No significant decline; continued normal cognition, etc.

If you were an official of the Australian drug approval agency, would you consider approving the drug for Australians being diagnosed with Alzheimer’s?

Is there any question that Anavex 2-73 is an efficacious Alzheimer's treatment drug?